"目录号: HY-13662
Membrane Transporter/Ion Channel-
Lansoprazole(AG-1749)是质子泵抑制剂，能抑制胃酸生成。
Proton Pump
相关产品
TAK-438-Omeprazole-Pantoprazole sodium-(R)-Lansoprazole-Zinc Pyrithione-AZD0865-Ilaprazole-Esomeprazole Magnesium trihydrate-Bamaquimast-Rabeprazole sodium-Soraprazan-Chebulinic acid-Picoprazole-SKF96067-Tenatoprazole sodium-
生物活性
Description
Lansoprazole(AG 1749) is a proton pump inhibitor which prevents the stomach from producing acid.Target: Proton PumpLansoprazole, a substituted benzimidizole proton pump inhibitor, on pharmacokinetics and metabolism of theophylline has been studied in healthy adults given oral lansoprazole 30 mg once daily for 11 days. On Days 4 and 11 of 300 mg aminophylline was simultaneously administered orally and blood samples for theophylline analysis were taken over 24 h [1]. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups [2]. lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 micrograms/ml, and fourfold more potent than that of omeprazole [3]. Clinical indications: Duodenal ulcer; Esophagitis; Gastroesophageal reflux; Gastrointestinal disease; Helicobacter pylori infection; Peptic ulcer; Stomach ulcer; Ulcer; Zollinger-Ellison syndromeFDA Approved Date: May 10, 1995Toxicity: Symptoms of overdose include abdominal pain, nausea and diarrhea.
Clinical Trial
NCT00175045
Takeda
Esophagitis-Reflux
June 2003
Phase 2
NCT01990339
Takeda
Gastroesophageal Reflux Disease With Dyspepsia Symptoms
December 2008
NCT01270308
Dr. Reddy's Laboratories Limited
Healthy
December 2008
Phase 1
NCT01040455
National Taiwan University Hospital-Takeda
Functional Dyspepsia
December 2009
Phase 4
NCT01778101
Seoul National University Hospital
Preterm Infants-Gastrointestinal Reflux
January 2013
Phase 2
NCT02170207
Takeda
Acute Stress Ulcer and Acute Gastric Mucosal Lesions
January 2007
NCT00701259
Novartis
Frequent Heartburn
January 2007
Phase 3
NCT02151786
Takeda
Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions
January 2007
NCT01135368
Takeda
Gastroesophageal Reflux
June 2002
Phase 4
NCT00390390
Novartis
Heartburn
June 2006
Phase 3
NCT01762657
Perle Bioscience, Inc.
Type 1 Diabetes
September 2014
Phase 3
NCT02099682
Takeda
Gastric or Duodenal Ulcers
August 2010
NCT01642602
Takeda
Gastroesophageal Reflux Disease
July 2012
Phase 2
NCT02099708
Takeda
Gastric or Duodenal Ulcers
October 2010
NCT01045967
Teva Pharmaceuticals USA
Healthy
May 2004
Phase 1
NCT00220818
Takeda
Gastroesophageal Reflux Disease
January 2005
Phase 1
NCT01046084
Teva Pharmaceuticals USA
Healthy
August 2003
Phase 1
NCT01046253
Teva Pharmaceuticals USA
Healthy
January 2004
Phase 1
NCT00708149
Far Eastern Memorial Hospital
Respiratory Failure
June 2009
Phase 4
NCT00644735
AstraZeneca
Erosive Esophagitis
December 2002
Phase 4
NCT00174928
Takeda
Gastroesophageal Reflux Disease
May 2005
Phase 1
NCT01008696
Janssen Korea, Ltd., Korea
Reflux Esophagitis
May 2007
Phase 4
NCT00787254
Takeda
Stomach Ulcer-Duodenal Ulcer
April 2007
Phase 3
NCT00458614
Arkansas Children's Hospital Research Institute
Cystic Fibrosis
June 2006
Phase 1
NCT00637845
AstraZeneca
Heartburn-Gastroesophageal Reflux Disease
June 2002
Phase 4
NCT00762359
Takeda
Stomach Ulcer-Duodenal Ulcer
May 2007
Phase 3
NCT00641602
AstraZeneca
Erosive Esophagitis
December 2002
Phase 4
NCT02064907
Takeda
Bioavailability
February 2014
Phase 1
NCT00369265
American Institute for Voice and Ear Research
Laryngopharyngeal Reflux
August 2006
Phase 4
NCT01155284
Sanford Health-Juvenile Diabetes Research Foundation
Type 1 Diabetes
August 2010
Phase 2
NCT00251719
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
December 2005
Phase 3
NCT00251693
Takeda
Esophagitis, Reflux-Esophagitis, Peptic
December 2005
Phase 3
NCT00324974
Takeda
Gastroesophageal Reflux Disease
June 2006
Phase 3
NCT02442752
Takeda
Pediatric Gastroesophageal Reflux Disease
February 2016
Phase 1
NCT00663897
Lotung Poh-Ai Hospital-Tomorrow Medical Foundation
Functional Dyspepsia-Epigastric Pain Syndrome-Post Prandial Distress Syndrome
May 2008
Phase 4
NCT02388737
Takeda
Erosive Esophagitis
April 2015
Phase 3
NCT02096458
Takeda
Gastroesophageal Reflux Disease-Erosive Esophagitis-Heartburn
February 2014
Phase 1
NCT00204373
Charles Mel Wilcox, MD-Takeda Pharmaceuticals North America, Inc.-University of Alabama at Birmingham
Zollinger-Ellison Syndrome-Multiple Endocrine Neoplasia
March 2003
Phase 4
NCT00352261
AstraZeneca
Barrett's Esophagus
January 2006
Phase 4
NCT01039558
Seoul National University Hospital
Gastroesophageal Reflux Disease
December 2009
NCT02616302
Takeda
Gastroesophageal Reflux
November 2015
Phase 2
NCT02334501
Puma Biotechnology, Inc.
Healthy
August 2014
Phase 1
NCT01317472
Indiana University
Laryngopharyngeal Reflux
March 2011
NCT02162758
Takeda
Barrett's Esophagus
July 2014
Phase 2
NCT00335283
Vanderbilt University-TAP Pharmaceutical Products Inc.
Larynx Disease
August 2006
Phase 3
NCT03050307
Takeda
Gastric Ulcer-Peptic Ulcer-Gastrointestinal Diseases-Digestive System Diseases-Lansoprazole-Anti-Ulcer Agents-Gastrointestinal Agents-Proton Pump Inhibitors-Enzyme Inhibitors-Molecular Mechanisms of Pharmacological Action
April 17, 2017
Phase 3
NCT01642615
Takeda
Gastroesophageal Reflux Disease-Erosive Esophagitis
July 2012
Phase 2
NCT01820104
Xijing Hospital
Healthy
March 2013
Phase 1
NCT02873702
Takeda
Erosive Esophagitis
December 31, 2016
Phase 3
NCT01459367
Takeda
Erosive Esophagitis
October 2011